Comparison of Two Intravenous Lipid Emulsions in Home Parenteral Nutrition Patients

Home Parenteral Nutrition Clinical Trial

Official title:

A Randomized Controlled Trial Comparing Two Commercially Available Lipid Emulsions in Patients Receiving Home Parenteral Nutrition - SMOF Versus Intralipid

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02796833
• Other study ID #: 14-8537-A
• Status: Completed
• Phase: Phase 4
• Start date: March 2016
• Est. completion date: December 2019

Study information

• Verified date: March 2020
• Source: University Health Network, Toronto
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Total Parenteral Nutrition (TPN) is a way of feeding a person intravenously, and is required when the gastrointestinal tract is not able to function properly. TPN contains carbohydrates, protein, and fat and lipids. It also contains minerals and vitamins. The lipid that is currently used at the University Health Network home TPN program is Intralipid20%, which is based on Soybean oil, contains polyunsaturated fats and is a good source of energy and essential fatty acids, including omega 3 and 6 fatty acids, which needed by the body. However, long term use on Intralipid20% has been shown to have negative effects on antioxidant status, inflammation, liver, and the immune system.

SMOFlipid20% is a lipid emulsion that has been designed to maximize the ratio of omega 3 to omega 6 fatty acids, in an effort to avoid potentially harmful effects associated with Intralipid20%. In previous studies, it has been shown that SMOFlipid20% is safe and has positive benefits on the liver enzymes. There are no studies so far which follow patient who is on SMOFlipid20% long term. The investigators hope to show that with long term use of SMOFlipid20% is better for liver function compared to Intralipid20%.

Description:

A prospective double-blind, crossover, randomized clinical trial of 13 months duration per participant to compare between 2 commercially available lipid emulsion, Intralipid vs SMOF, in patient receiving home parenteral nutrition (HPN). All subjects are stable HPN patients who receive Intralipid as lipid emulsion in their solutions. The subjects will be randomized to two groups. One group will receive Intralipid for 6 months, followed by 28 days of wash-out period, and then will receive SMOF for 6 months. Another groups will receive SMOF in first 6 months, followed by 28 days of wash-out period, then will receive Intralipid for 6 months. During wash-out period for both groups, the patients will receive Intralipid as standard lipid emulsion. Each patient will have 4 clinic visits at Toronto General Hospital for clinical interview, nutritional measurements, routine blood tests, and special blood tests at baseline then at 6, 7, 13 months. Also, the patients will be asked to have routine blood tests after month 3 and month 9. The patients will fill the food record which will be collected later after completion of each period, month 6 and 13 of the study. The investigators will be calling patients during both periods to check compliance and update on their condition including the adverse events.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: December 2019
• Est. primary completion date: December 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Signed and dated informed consent form (ICF) to participate before any study related procedures are performed

• Adult over the age of 18

• Both males and females

• Clinically stable for at least 4 weeks with no acute medical co-morbidities

• Patients on a stable Intralipid HPN regimen for 6 months and expected to require long-term PN for at least 13 more months

Exclusion Criteria:

Subjects not already on Intralipid PN Inability to give informed consent Alcohol or drug abuse Pregnant and lactating women

Clinical instability such as the following:

• Acute pulmonary edema

• Decompensated heart failure

• Decompensated chronic liver disease

• Severe post-traumatic conditions

• Uncontrolled diabetes mellitus

• Acute myocardial infarction

• Acute stroke

• Acute thromboembolism

• Metabolic acidosis

• Sepsis

• Hypotonic dehydration

• Coagulopathy with prolonged aPTT or INR Elevated triglyceride level: more than 4.5 mmol/L Active malignancy with life expectancy less than one year Subjects who are hypersensitive or allergic to the product ingredients of SMOF or Intralipid, including soybean oil, peanuts, fish oil, and egg as well as allergy to peanuts.

Related Conditions & MeSH terms

• Home Parenteral Nutrition

Intervention

Drug:
• SMOFlipid20%

Locations

Country	Name	City	State
Canada	Toronto General Hospital, University Health Network	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Johane Allard

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	change in alanine transaminase (ALT)		baseline 1, 6 months, baseline 2 (7 mo), 13 months
Secondary	changes in liver function tests (total and conjugated bilirubin, ALP, AST, GGT)		baseline 1, 6 months, baseline 2 (7 mo), 13 months
Secondary	rate of infections (central line and other) per 1000 catheter days		baseline 1, 6 months, baseline 2 (7 mo), 13 months
Secondary	antibiotic days for acute infections		baseline 1, 6 months, baseline 2 (7 mo), 13 months
Secondary	number of hospitalizations for the past 6 months		baseline 1, 6 months, 13 months
Secondary	number of catheter changes for the past 6 months		baseline 1, 6 months, 13 months